Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: A preliminary observation

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 51-56

  Fornaro, Michele ^a   Martino, Matteo ^a   Battaglia, Florinda ^b   Colicchio, Salvatore ^c   Perugi, Giulio ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b Center of Excellence for Biomedical Research (CEBR)   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Duloxetine; Interleukin 6 (IL 6); Major depressive disorder (MDD)

Indexed keywords

DULOXETINE; INTERLEUKIN 6;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INDUCED HEADACHE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MONOTHERAPY; NAUSEA; TREATMENT DURATION; YOUNG MANIA RATING SCALE;

EID: 79951614138     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S16382     Document Type: Article

References (36)

1. Hickie I, Lloyd A. Are cytokines associated with neuropsychiatric syndromes in humans? Int J Immunopharmacol. 1995; 17(8): 677-683.
2. Elenkov IJ. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int. 2008; 52(1-2):40-51.
3. Schlatter J, Ortuno F, Cervera-Enguix S. Monocytic parameters in patients with dysthymia versus major depression. J Affect Disord. 2004; 78(3):243-247.
4. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol. 1999; 461:25-46.
5. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000; 22(4):370-379.
6. Gill J, Vythilingam M, Page GG. Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J Trauma Stress. 2008; 21(6):530-539.
7. Sutherland AG, Alexander DA, Hutchison JD. Disturbance of pro-inflammatory cytokines in post-traumatic psychopathology. Cytokine. 2003; 24(5):219-225.
8. Konuk N, Tekin IO, Ozturk U, et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder. Mediators Infamm. 2007:65704.
9. Cramer AO, Waldorp LJ, van der Maas HL, Borsboom D. Comorbidity: a network perspective. Behav Brain Sci. 2010; 33(2-3):137-150; discussion 150-193.
10. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol. 2010; 25(3):201-215.
11. Reseland S. Is current prescription practice of SSRI justifiable?. Tidsskr Nor Laegeforen. 2003; 123(18):2621.
12. De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol. 2010; 23(2): 417-422.
13. Kubera M, Kenis G, Bosmans E, et al. Stimulatory effect of anti depressants on the production of IL-6. Int Immunopharmacol. 2004; 4(2): 185-192.
14. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychop-harmacol. 2001; 21(2):199-206.
15. Vollmar P, Haghikia A, Dermietzel R, Faustmann PM. Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. Int J Neuropsychopharmacol. 2008; 11(1):111-117.
16. Piletz JE, Halaris A, Iqbal O, et al. Pro-inflammatory bio makers in depression: treatment with venlafaxine. World J Biol Psychiatry. 2008: 1-11.
17. Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007; 10(1):51-61.
18. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008; 23(3):161-169.
19. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. 4th ed. Washington: American Psychiatric Association; 1994.
20. Ventura J, Liberman R P, Green MF, Shaner A, Mintz J. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res. 1998; 79(2):163-173.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
22. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978; 133: 429-435.
23. Maes M, Scharpe S, Meltzer HY, et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypo-thalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 1993; 49(1):11-27.
24. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res. 1997; 43(5):529-534.
25. Kagaya A, Kugaya A, Takebayashi M, et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology. 2001; 43(2):59-62.
26. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999; 40(4):171-176.
27. Kubera M, Kenis G, Bosmans E, et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol. 2000; 52(3):237-241.
28. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci. 1997; 247(4):228-233.
29. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002; 5(4):401-412.
30. Xia Z, DePierre J W, Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology. 1996; 34(1):27-37.
31. Maes M, Song C, Lin AH, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 1999; 20(4): 370-379.
32. Budziszewska B, Basta-Kaim A, Kubera M, et al. Effect of lipopolysac-charide and antidepressant drugs on glucocorticoid receptor-mediated gene transcription. Pharmacol Rep. 2005; 57(4):540-544.
33. Wang W, Danielsson A, Svanberg E, Lundholm K. Lack of effects by tricyclic antidepressant and serotonin inhibitors on anorexia in MCG 101 tumor-bearing mice with eicosanoid-related cachexia. Nutrition. 2003; 19(1):47-53.
34. Shen Y, Connor TJ, Nolan Y, Kelly J P, Leonard BE. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci. 1999; 65(17):1773-1786.
35. Hashioka S, Klegeris A, Monji A, et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol. 2007; 206(1):33-42.
36. Elenkov IJ, Chrousos G.P. Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol Metab. 1999; 10(9):359-368.